Compare Natera Inc. Common Stock (NTRA) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Teucrium Wheat Fund — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Teucrium Wheat Fund trades at $24.38 (market cap $274.59M). The key difference: Natera Inc. Common Stock is far larger — about 207.7× Teucrium Wheat Fund's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Teucrium Wheat Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Teucrium Wheat Fund for 42 Days on average.
| NTRA | WEAT | |
|---|---|---|
Market Cap | $57.03B | $274.59M |
Volume | 1,131,157 | 203,622 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $425.64 | $28.00 |
52-Week Low | $179.42 | $19.88 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
WEAT trades at $24.28, down 0.74% today, with a bearish technical signal from moving averages. Recent news highlights a 25% year-to-date gain as of July 2026, driven by wheat market dynamics, though inflation concerns persist. Key support is at $24, with resistance at $25. The absence of fundamental ratios like P/E and P/S in the data limits valuation clarity, but the ETF's performance is tied to agricultural commodity trends.
The outlook is cautious due to bearish technical indicators and macroeconomic inflation pressures. Opportunities exist if wheat prices rally, but risks include commodity volatility and Federal Reserve policy impacts. Investors should weigh the ETF's lack of traditional company fundamentals against broader market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
